25 Years of Pancreatic Cell Transplants: What the Edmonton Protocol Has Taught Us

Type 1 diabetes develops when the immune system destroys the beta cells in the pancreas that produce insulin. For decades, insulin injections have been the standard way to replace what the body can no longer make on its own.

The Edmonton protocol introduced a different approach: transplanting beta cells from donor pancreases directly into people with Type 1 diabetes. The goal is to restore the body's ability to produce insulin naturally and regulate blood sugar the way it does in people without diabetes.

By achieving more physiological insulin control, cell transplantation also aims to reduce the risk of diabetes-related complications—from heart and kidney disease to vision problems.

The Edmonton protocol has now been in clinical use for 25 years, giving researchers substantial real-world data about how the approach works, where it succeeds, and where it falls short.

Clinical evidence shows genuine benefits: transplanted beta cells can function and produce insulin in recipients. However, the protocol also faces limitations—challenges that have become the focus of ongoing research and refinement.

One of the biggest obstacles with the Edmonton protocol is the scarcity of donor pancreases. There simply aren't enough available to meet the demand.

Recent advances in stem cell science offer a potential solution. Researchers are developing ways to grow insulin-producing beta cells from stem cells in the laboratory, which could eventually provide a much larger and more reliable supply of cells for transplantation.

These new approaches hold promise for overcoming the Edmonton protocol's limitations and improving the chances of long-term diabetes remission. While the science is still advancing, the direction is clear: moving from reliance on scarce donor organs toward a more sustainable path forward.

Twenty-five years of clinical data have validated the concept that beta cell transplantation can work for Type 1 diabetes. At the same time, that experience has revealed the practical challenges that need solving.

As stem cell differentiation and transplantation technology continue to improve, researchers are working toward protocols that could deliver more reliable, long-lasting remission with fewer barriers to access. The goal remains the same: restoring the body's natural ability to produce and regulate insulin.

Source: Medecine sciences : M/S. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.